RxDoctor Payments Data

Prit Sinchai, MD

Ophthalmology · Orange, CANPI 1528191269

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 57 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$417
  • Optos, Inc.$158
  • Rxsight Inc$82
  • Aerie Pharmaceuticals, Inc.$75
  • Shire North American Group Inc$73
  • Alcon$60
  • plus $395 from 16 others

What the payments were for

  • Food & beverage$85067%
  • Education$23319%
  • Gifts$192%
  • Entertainment$15813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260 in reported general payments places this provider in the 45th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$273,398
Medicare patients
581
Services billed
2,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine154$123,995
XiidraLifitegrast72$67,328
Cyclosporine72$46,939
LumiganBimatoprost70$34,652
RocklatanNetarsudil Mesylat/Latanoprost33$23,356
Alphagan PBrimonidine Tartrate34$17,093
Brimonidine Tartrate141$16,404
SimbrinzaBrinzolamide/Brimonidine Tart36$10,772
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$7,700
Tobramycin-DexamethasoneTobramycin/Dexamethasone120$6,944
Latanoprost578$6,608
Travoprost29$5,741
Prednisolone Acetate229$5,707
VyzultaLatanoprostene Bunod13$5,041
RhopressaNetarsudil Mesylate11$4,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$417$175,740258 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$19$72,36985 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$75$28,24644 claims
AlconSimbrinza$60$10,77236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →